A review article defines LIDDS as a key player in TLR9 agonist research field and being the only provider having a sustained release product in development

NEXT STORY
FDA Grants Breakthrough Designation to 4D Path for Novel Cancer Diagnostic Solution
PREV STORY
Cerner Announces Appointment of Major General Elder Granger, M.D., United States Army (Retired) to Its Board of Directors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020

author_avatar
NASDAQ Market News

Zai Lab Announces Pricing of Public Offering of American Depositary Shares

SHANGHAI, China, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or ...

author_avatar
NASDAQ Market News

BioXcel Therapeutics Launches “Boiling Point” Educational Campaign to Shed Light on the Importance of Prompt and Cooperative De-escalation in the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders

author_avatar
NASDAQ Market News